Released Aug 16, 2021, after the close
10-Q filed Aug 16, 2021, 47 days after period end · 0001193125-21-247879
Q2 2021 · 10-Q
Revenue—
Net Income-$61.36M-$61.36M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$141.93-$141.93 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$3,441,000N/M
Operating Cash Flowderived-$4,264,000—
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Net Income | -$61.36M | -$2.04M |
| EPS Diluted | -$141.93 | -$4.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR